Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Saudi Pharm J
2023 Jul 01;317:1265-1273. doi: 10.1016/j.jsps.2023.05.014.
Show Gene links
Show Anatomy links
Piperazine amides with desirable solubility, physicochemical and drug-like properties: Synthesis and evaluation of the anti-Trypanosoma cruzi activity.
Varela MT
,
Romanelli M
,
Amaral M
,
Tempone AG
,
Fernandes JPS
.
???displayArticle.abstract???
The absence of effective chronic treatment, expansion to non-endemic countries and the significant burden in public health have stimulated the search for novel therapeutic options to treat Chagas disease, a protozoan disease caused by Trypanosoma cruzi. Despite current efforts, no new drug candidates were approved in clinical trials in the past five decades. Considering this, our group has focused on the expansion of a series (LINS03) with low micromolar activity against amastigotes, considering the optimization of pharmacokinetic properties through increasing drug-likeness and solubility. In this work, we report a new set of 13 compounds with modifications in both the arylpiperazine and the aromatic region linked by an amide group. Five analogues showed activity against intracellular amastigotes (IC50 17.8 to 35.9 µM) and no relevant cytotoxicity to mammalian cells (CC50 > 200 µM). Principal component analysis (PCA) was performed to identify structural features associated to improved activity. The data revealed that polarity, hydrogen bonding ability and flexibility were key properties that influenced the antiparasitic activity. In silico drug-likeness assessments indicated that compounds with the 4-methoxycinammyl (especially compound 2b) had the most prominent balance between properties and activity in the series, as confirmed by SAR analysis.
Amaral,
A semi-synthetic neolignan derivative from dihydrodieugenol B selectively affects the bioenergetic system of Leishmania infantum and inhibits cell division.
2019, Pubmed
Amaral,
A semi-synthetic neolignan derivative from dihydrodieugenol B selectively affects the bioenergetic system of Leishmania infantum and inhibits cell division.
2019,
Pubmed
Aulner,
Next-Generation Phenotypic Screening in Early Drug Discovery for Infectious Diseases.
2019,
Pubmed
Castro,
Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis).
2006,
Pubmed
Cavalieri,
Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases.
2002,
Pubmed
Daina,
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.
2017,
Pubmed
Don,
Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections.
2014,
Pubmed
Gilbert,
Drug discovery for neglected diseases: molecular target-based and phenotypic approaches.
2013,
Pubmed
Guo,
The modification of natural products for medical use.
2017,
Pubmed
Katsuno,
Hit and lead criteria in drug discovery for infectious diseases of the developing world.
2015,
Pubmed
Kratz,
Drug discovery for chagas disease: A viewpoint.
2019,
Pubmed
Kratz,
Clinical and pharmacological profile of benznidazole for treatment of Chagas disease.
2018,
Pubmed
Mansoldo,
Chagas Disease: Perspectives on the Past and Present and Challenges in Drug Discovery.
2020,
Pubmed
Morillo,
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
2015,
Pubmed
Pantaleão,
Recent Advances in the Prediction of Pharmacokinetics Properties in Drug Design Studies: A Review.
2022,
Pubmed
Romanelli,
Mitochondrial Imbalance of Trypanosoma cruzi Induced by the Marine Alkaloid 6-Bromo-2'-de-N-Methylaplysinopsin.
2022,
Pubmed
Shi,
Predicting Human Pharmacokinetics: Physiologically Based Pharmacokinetic Modeling and In Silico ADME Prediction in Early Drug Discovery.
2019,
Pubmed
Shikanai-Yasuda,
Oral transmission of Chagas disease.
2012,
Pubmed
Sohlenius-Sternbeck,
Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department.
2016,
Pubmed
Tada,
An improved colorimetric assay for interleukin 2.
1986,
Pubmed
Tandon,
Polarizability: a promising descriptor to study chemical-biological interactions.
2021,
Pubmed
Varela,
Antiparasitic activity of new gibbilimbol analogues and SAR analysis through efficiency and statistical methods.
2018,
Pubmed
,
Echinobase
Varela,
Evaluation of the antitrypanosoma activity and SAR study of novel LINS03 derivatives.
2019,
Pubmed
,
Echinobase
Varela,
Optimization of physicochemical properties is a strategy to improve drug-likeness associated with activity: Novel active and selective compounds against Trypanosoma cruzi.
2022,
Pubmed
Zhu,
Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis.
2002,
Pubmed
